Hagino Hiroshi
School of Health Science, Faculty of Medicine, Tottori University.
Nihon Rinsho. 2009 May;67(5):948-53.
Risedronate is effective and approved for the treatment of osteoporosis in Japan. Risedronate decreases strongly bone resorption and turnover via a potent inhibitory action on osteoclasts. Risedronate was shown to significantly decrease the risk of nonvertebral fractures including hip fractures as well as vertebral fractures in placebo-controlled, 3-year clinical trials in postmenopausal women with osteoporosis. The efficacy of risedronate elucidated by recent clinical studies was reviewed.
利塞膦酸盐在日本被证明对治疗骨质疏松症有效且已获批准。利塞膦酸盐通过对破骨细胞的强大抑制作用,强烈降低骨吸收和骨转换。在针对患有骨质疏松症的绝经后女性的安慰剂对照3年临床试验中,利塞膦酸盐被证明可显著降低包括髋部骨折在内的非椎体骨折以及椎体骨折的风险。本文对近期临床研究阐明的利塞膦酸盐的疗效进行了综述。